June 8, 2026

•

XX

min read

Artificial intelligence has become a permanent layer in pharmaceutical R&D, and it is generating a distinctive, fast-growing patent landscape. The convergence of AI and drug discovery is visible directly in the data on generative-AI patenting: among the categories tracked by the World Intellectual Property Organization, applications in molecules, genes, and proteins, though smaller in absolute number at roughly 1,500 inventions, were the fastest-growing, expanding at about 78 percent per year over a five-year period.¹ Peer-reviewed patent-basis analysis of AI in the pharmaceutical industry confirms both the rapid rise of filing activity and its concentration among a set of key players,² and a growing body of work applies patent-landscaping and bibliometric methods specifically to AI-driven drug discovery, including in areas such as cancer drug discovery.⁵,⁶,⁷ For R&D and IP teams, the strategic questions are which sub-domains are crowded, where defensible white space remains, and how the unsettled rules on AI-assisted inventorship affect what can be protected.

The landscape divides into several technically distinct sub-domains, each a different region of patenting. Generative molecular design covers models that propose novel candidate molecules. Drug-target interaction and binding-affinity prediction covers models that predict whether and how strongly a molecule binds a target. Drug repurposing covers methods that use biomedical knowledge graphs and network pharmacology to find new uses for known compounds. Multi-omics response prediction covers models that predict biological response from genomic and other omics data. Clinical-trial prediction and design covers models that forecast trial success and optimize design. And a further layer covers AI-assisted pharmaceutical development and, increasingly, generative AI applied to regulatory documentation. These sub-domains differ sharply in how crowded they are: biomedical knowledge-graph construction and traversal, for example, has become a comparatively crowded area of prior art, while newer large-language-model-native and agentic approaches are earlier and sparser.

Two structural features shape the landscape. The first is geographic and institutional concentration: the same concentration seen across generative AI, where a small number of countries account for most filings, extends into AI drug discovery, with China's share of generative-AI patenting near the top globally.¹ The second is the unsettled status of AI-assisted inventorship. In the United States, the Patent and Trademark Office rescinded its February 2024 guidance on AI-assisted inventions in November 2025 and returned to the traditional human-conception standard, which affects how AI-heavy pipelines document invention and how their patents should be valued.³ Commentators expect the first wave of litigation over AI-generated drug inventions within a few years, which will set precedents on inventorship and eligibility.⁴ These are not peripheral legal details; they determine what portion of an AI-driven discovery effort can be protected and how a portfolio should be structured, and they vary by jurisdiction. Because applications publish about eighteen months after filing, the newest large-language-model-native and agentic filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

What the AI drug discovery landscape shows

Fastest-growing generative-AI category. Among generative-AI patents, molecule, gene, and protein applications grew fastest, at roughly 78 percent per year, though from a smaller base than image or text applications.¹

Several distinct sub-domains. The field spans generative molecular design, drug-target interaction prediction, knowledge-graph-based repurposing, multi-omics response prediction, clinical-trial prediction, and AI-assisted development.²

Crowded versus sparse areas. Biomedical knowledge-graph construction and traversal is comparatively crowded prior art, while large-language-model-native and agentic approaches are earlier and sparser.

Geographic concentration. Activity is concentrated in a small number of countries, mirroring the broader generative-AI landscape, with China prominent.¹

Unsettled inventorship. AI-assisted inventorship rules are in flux, with the US returning to a human-conception standard in late 2025, which affects what can be protected and how portfolios are documented.³,⁴

How AI-powered landscape and white space analysis helps

Mapping a fast-moving, sub-domain-structured field where much of the state of the art is in non-patent literature requires more than keyword search. AI-powered analysis addresses this with semantic search across both patents and scientific literature, which is essential because AI-method disclosures often appear first in preprints and conference proceedings, attribution that normalizes filers to canonical entities, and continuous monitoring that tracks the newest agentic and large-language-model-native filings. Clustering activity by sub-domain and by concept is what distinguishes crowded prior art from genuine white space.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving, literature-heavy fields such as AI in drug discovery across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. Because the corpus spans both patents and scientific literature, Cypris covers the preprints and conference proceedings where AI-method disclosures often appear first, rather than patents alone. The ontology clusters activity by sub-domain, generative design, interaction prediction, repurposing, multi-omics, and clinical prediction, and normalizes filers to canonical entities, so a team can resolve which areas, such as knowledge-graph methods, are crowded and which, such as agentic approaches, remain open as white space. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined area over time and flags new patents and papers as they publish, which is essential where the newest filings are under-represented by publication lag. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is AI drug discovery patenting growing?

AI drug discovery patenting is growing quickly. Among generative-AI patent categories tracked by WIPO, applications in molecules, genes, and proteins were the fastest-growing at roughly 78 percent per year, though from a smaller base than image or text applications. Peer-reviewed patent-basis analysis confirms the rapid rise of AI filing activity in the pharmaceutical industry.

What are the main sub-domains of AI drug discovery patents?

The main sub-domains are generative molecular design, drug-target interaction and binding-affinity prediction, drug repurposing using biomedical knowledge graphs, multi-omics response prediction, clinical-trial prediction and design, and AI-assisted pharmaceutical development. Each is a technically distinct region of the patent landscape. They differ substantially in how crowded they are.

Which areas of AI drug discovery are crowded, and which are open?

Biomedical knowledge-graph construction and traversal has become a comparatively crowded area of prior art in AI drug discovery, while large-language-model-native and agentic approaches are earlier and sparser. The crowded areas carry more freedom-to-operate risk, and the sparser areas hold more white space. Distinguishing them requires clustering activity by sub-domain and concept.

How does AI-assisted inventorship affect drug patents?

AI-assisted inventorship affects drug patents because the rules on whether and how AI-assisted inventions can be protected are unsettled and vary by jurisdiction. In the United States, the Patent and Trademark Office rescinded its 2024 guidance on AI-assisted inventions in November 2025 and returned to the traditional human-conception standard. This affects how AI-heavy pipelines document invention and how their patents are valued.

Why does China feature prominently in AI drug discovery patenting?

China features prominently in AI drug discovery patenting because it accounts for a large share of generative-AI patenting overall, and that concentration extends into the drug discovery sub-domains. The broader generative-AI landscape is dominated by a small number of countries. This geographic concentration matters for competitive positioning and freedom-to-operate.

Why does AI drug discovery analysis need scientific literature?

AI drug discovery analysis needs scientific literature because AI-method disclosures often appear first in preprints and conference proceedings rather than patents, so a patent-only view misses much of the state of the art. This is characteristic of AI fields generally. Cypris analyzes both patents and scientific literature across more than 500 million documents.

How do you find white space in AI drug discovery?

Finding white space in AI drug discovery means clustering activity by sub-domain and concept across patents and scientific literature, and identifying the sparser areas, such as agentic and large-language-model-native approaches, where few patents yet exist. Because much of the state of the art is in non-patent literature, semantic search across both sources is essential. The white space is where a viable method exists but patenting is still thin.

Which teams use AI drug discovery patent landscape analysis?

AI drug discovery patent landscape analysis is used by R&D, IP, and strategy teams at pharmaceutical companies, AI-native drug discovery firms, and their partners, as well as investors assessing AI-driven pipelines. It informs where to file, where freedom-to-operate risk sits, and how to structure a portfolio given inventorship uncertainty. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does an AI drug discovery landscape need to be?

An AI drug discovery landscape needs to be continuously current, because the field moves quickly, inventorship rules are shifting, new agentic and large-language-model-native filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages within months. Cypris uses Agentic Monitoring to track a defined area and flag new patents and papers as they publish.

Endnotes

World Intellectual Property Organization (2024). Patent Landscape Report: Generative Artificial Intelligence. Geneva: WIPO. https://doi.org/10.34667/tind.49740
Kano, S. & Sakaoka, S. (2025). Quantitative insights on artificial intelligence in the pharmaceutical industry: a patent-basis analysis of technological trends and key players. World Patent Information. https://www.sciencedirect.com/science/article/pii/S0172219025000481
United States Patent and Trademark Office (2025). Revised Inventorship Guidance for AI-Assisted Inventions, Federal Register (published November 28, 2025; rescinding the February 2024 guidance and returning to the traditional human-conception standard). https://www.federalregister.gov/documents/2025/11/28/2025-21457/revised-inventorship-guidance-for-ai-assisted-inventions
Goodwin (2026). AI Drug Discovery Tests the Limits of Patent Law. https://www.goodwinlaw.com/en/insights/publications/2025/12/insights-lifesciences-ip-ai-drug-discovery-tests-the-limits-of-patent-law
Hofmann-Apitius, M., Gadiya, Y., Zaliani, A. & Gribbon, P. (2023). Pharmaceutical patent landscaping: a novel approach to understand patents from the drug discovery perspective. Artificial Intelligence in the Life Sciences. https://doi.org/10.1016/j.ailsci.2023.100061
Abdulwahab, A. A. et al. (2024). Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency. Pharmaceutical Patent Analyst.
Jing, F. & Ma, Y. (2024). Bibliometric Analysis and Research Trends in Artificial Intelligence for Pharmaceutical Management and Drug Discovery.

‍

AI in Drug Discovery: The Patent Landscape in 2026

Table of contents

Register here

Subscribe to receive the latest blog posts to your inbox every week.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Artificial intelligence has become a permanent layer in pharmaceutical R&D, and it is generating a distinctive, fast-growing patent landscape. The convergence of AI and drug discovery is visible directly in the data on generative-AI patenting: among the categories tracked by the World Intellectual Property Organization, applications in molecules, genes, and proteins, though smaller in absolute number at roughly 1,500 inventions, were the fastest-growing, expanding at about 78 percent per year over a five-year period.¹ Peer-reviewed patent-basis analysis of AI in the pharmaceutical industry confirms both the rapid rise of filing activity and its concentration among a set of key players,² and a growing body of work applies patent-landscaping and bibliometric methods specifically to AI-driven drug discovery, including in areas such as cancer drug discovery.⁵,⁶,⁷ For R&D and IP teams, the strategic questions are which sub-domains are crowded, where defensible white space remains, and how the unsettled rules on AI-assisted inventorship affect what can be protected.

The landscape divides into several technically distinct sub-domains, each a different region of patenting. Generative molecular design covers models that propose novel candidate molecules. Drug-target interaction and binding-affinity prediction covers models that predict whether and how strongly a molecule binds a target. Drug repurposing covers methods that use biomedical knowledge graphs and network pharmacology to find new uses for known compounds. Multi-omics response prediction covers models that predict biological response from genomic and other omics data. Clinical-trial prediction and design covers models that forecast trial success and optimize design. And a further layer covers AI-assisted pharmaceutical development and, increasingly, generative AI applied to regulatory documentation. These sub-domains differ sharply in how crowded they are: biomedical knowledge-graph construction and traversal, for example, has become a comparatively crowded area of prior art, while newer large-language-model-native and agentic approaches are earlier and sparser.

Two structural features shape the landscape. The first is geographic and institutional concentration: the same concentration seen across generative AI, where a small number of countries account for most filings, extends into AI drug discovery, with China's share of generative-AI patenting near the top globally.¹ The second is the unsettled status of AI-assisted inventorship. In the United States, the Patent and Trademark Office rescinded its February 2024 guidance on AI-assisted inventions in November 2025 and returned to the traditional human-conception standard, which affects how AI-heavy pipelines document invention and how their patents should be valued.³ Commentators expect the first wave of litigation over AI-generated drug inventions within a few years, which will set precedents on inventorship and eligibility.⁴ These are not peripheral legal details; they determine what portion of an AI-driven discovery effort can be protected and how a portfolio should be structured, and they vary by jurisdiction. Because applications publish about eighteen months after filing, the newest large-language-model-native and agentic filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

What the AI drug discovery landscape shows

Fastest-growing generative-AI category. Among generative-AI patents, molecule, gene, and protein applications grew fastest, at roughly 78 percent per year, though from a smaller base than image or text applications.¹

Several distinct sub-domains. The field spans generative molecular design, drug-target interaction prediction, knowledge-graph-based repurposing, multi-omics response prediction, clinical-trial prediction, and AI-assisted development.²

Crowded versus sparse areas. Biomedical knowledge-graph construction and traversal is comparatively crowded prior art, while large-language-model-native and agentic approaches are earlier and sparser.

Geographic concentration. Activity is concentrated in a small number of countries, mirroring the broader generative-AI landscape, with China prominent.¹

Unsettled inventorship. AI-assisted inventorship rules are in flux, with the US returning to a human-conception standard in late 2025, which affects what can be protected and how portfolios are documented.³,⁴

How AI-powered landscape and white space analysis helps

Mapping a fast-moving, sub-domain-structured field where much of the state of the art is in non-patent literature requires more than keyword search. AI-powered analysis addresses this with semantic search across both patents and scientific literature, which is essential because AI-method disclosures often appear first in preprints and conference proceedings, attribution that normalizes filers to canonical entities, and continuous monitoring that tracks the newest agentic and large-language-model-native filings. Clustering activity by sub-domain and by concept is what distinguishes crowded prior art from genuine white space.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving, literature-heavy fields such as AI in drug discovery across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. Because the corpus spans both patents and scientific literature, Cypris covers the preprints and conference proceedings where AI-method disclosures often appear first, rather than patents alone. The ontology clusters activity by sub-domain, generative design, interaction prediction, repurposing, multi-omics, and clinical prediction, and normalizes filers to canonical entities, so a team can resolve which areas, such as knowledge-graph methods, are crowded and which, such as agentic approaches, remain open as white space. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined area over time and flags new patents and papers as they publish, which is essential where the newest filings are under-represented by publication lag. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is AI drug discovery patenting growing?

AI drug discovery patenting is growing quickly. Among generative-AI patent categories tracked by WIPO, applications in molecules, genes, and proteins were the fastest-growing at roughly 78 percent per year, though from a smaller base than image or text applications. Peer-reviewed patent-basis analysis confirms the rapid rise of AI filing activity in the pharmaceutical industry.

What are the main sub-domains of AI drug discovery patents?

The main sub-domains are generative molecular design, drug-target interaction and binding-affinity prediction, drug repurposing using biomedical knowledge graphs, multi-omics response prediction, clinical-trial prediction and design, and AI-assisted pharmaceutical development. Each is a technically distinct region of the patent landscape. They differ substantially in how crowded they are.

Which areas of AI drug discovery are crowded, and which are open?

Biomedical knowledge-graph construction and traversal has become a comparatively crowded area of prior art in AI drug discovery, while large-language-model-native and agentic approaches are earlier and sparser. The crowded areas carry more freedom-to-operate risk, and the sparser areas hold more white space. Distinguishing them requires clustering activity by sub-domain and concept.

How does AI-assisted inventorship affect drug patents?

AI-assisted inventorship affects drug patents because the rules on whether and how AI-assisted inventions can be protected are unsettled and vary by jurisdiction. In the United States, the Patent and Trademark Office rescinded its 2024 guidance on AI-assisted inventions in November 2025 and returned to the traditional human-conception standard. This affects how AI-heavy pipelines document invention and how their patents are valued.

Why does China feature prominently in AI drug discovery patenting?

China features prominently in AI drug discovery patenting because it accounts for a large share of generative-AI patenting overall, and that concentration extends into the drug discovery sub-domains. The broader generative-AI landscape is dominated by a small number of countries. This geographic concentration matters for competitive positioning and freedom-to-operate.

Why does AI drug discovery analysis need scientific literature?

AI drug discovery analysis needs scientific literature because AI-method disclosures often appear first in preprints and conference proceedings rather than patents, so a patent-only view misses much of the state of the art. This is characteristic of AI fields generally. Cypris analyzes both patents and scientific literature across more than 500 million documents.

How do you find white space in AI drug discovery?

Finding white space in AI drug discovery means clustering activity by sub-domain and concept across patents and scientific literature, and identifying the sparser areas, such as agentic and large-language-model-native approaches, where few patents yet exist. Because much of the state of the art is in non-patent literature, semantic search across both sources is essential. The white space is where a viable method exists but patenting is still thin.

Which teams use AI drug discovery patent landscape analysis?

AI drug discovery patent landscape analysis is used by R&D, IP, and strategy teams at pharmaceutical companies, AI-native drug discovery firms, and their partners, as well as investors assessing AI-driven pipelines. It informs where to file, where freedom-to-operate risk sits, and how to structure a portfolio given inventorship uncertainty. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does an AI drug discovery landscape need to be?

An AI drug discovery landscape needs to be continuously current, because the field moves quickly, inventorship rules are shifting, new agentic and large-language-model-native filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages within months. Cypris uses Agentic Monitoring to track a defined area and flag new patents and papers as they publish.

Endnotes

World Intellectual Property Organization (2024). Patent Landscape Report: Generative Artificial Intelligence. Geneva: WIPO. https://doi.org/10.34667/tind.49740
Kano, S. & Sakaoka, S. (2025). Quantitative insights on artificial intelligence in the pharmaceutical industry: a patent-basis analysis of technological trends and key players. World Patent Information. https://www.sciencedirect.com/science/article/pii/S0172219025000481
United States Patent and Trademark Office (2025). Revised Inventorship Guidance for AI-Assisted Inventions, Federal Register (published November 28, 2025; rescinding the February 2024 guidance and returning to the traditional human-conception standard). https://www.federalregister.gov/documents/2025/11/28/2025-21457/revised-inventorship-guidance-for-ai-assisted-inventions
Goodwin (2026). AI Drug Discovery Tests the Limits of Patent Law. https://www.goodwinlaw.com/en/insights/publications/2025/12/insights-lifesciences-ip-ai-drug-discovery-tests-the-limits-of-patent-law
Hofmann-Apitius, M., Gadiya, Y., Zaliani, A. & Gribbon, P. (2023). Pharmaceutical patent landscaping: a novel approach to understand patents from the drug discovery perspective. Artificial Intelligence in the Life Sciences. https://doi.org/10.1016/j.ailsci.2023.100061
Abdulwahab, A. A. et al. (2024). Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency. Pharmaceutical Patent Analyst.
Jing, F. & Ma, Y. (2024). Bibliometric Analysis and Research Trends in Artificial Intelligence for Pharmaceutical Management and Drug Discovery.

‍

Keep Reading

July 17, 2026

•

XX

min read

Keyword search matches exact terms. Semantic search matches meaning. For patent search, that distinction determines whether a strategically critical filing is found or missed.

Patent search has relied on Boolean keyword queries and classification codes for decades. The method works when the searcher already knows the exact language an invention will use. It fails when a competitor describes the same mechanism with different words, files under a different classification, or uses terminology that did not exist when the query was written. In fast-moving fields, that failure is routine.

In 2026, R&D and IP teams are moving to AI-native semantic patent search because the volume and linguistic variety of global filings have outpaced keyword methods. This article defines semantic search, contrasts it with keyword search, and explains what the shift changes for patent search, patent analytics, prior art, and freedom-to-operate work.

How keyword patent search works and where it breaks

Keyword search retrieves documents that contain the specific terms in a query, usually combined with Boolean operators and classification filters. It is precise when the vocabulary is known and stable, and it remains useful for targeted lookups.

It breaks on vocabulary mismatch. Two teams working on the same problem often use entirely different terminology, and patent drafters frequently choose broad or unusual language deliberately. A keyword query built around expected terms will not retrieve a filing that describes the same invention differently. The result is silent gaps: the searcher sees results and assumes coverage, without knowing what was missed.

Volume magnifies the problem. Global patent filings and scientific publications continue to rise, and the World Intellectual Property Organization reported scientific output above two million articles in 2025. Expanding keyword queries to chase this volume produces either too much noise or too little signal.

How semantic search works

Semantic search represents the meaning of text as mathematical vectors, so that conceptually similar passages sit close together regardless of exact wording. A query for a mechanism retrieves filings that describe that mechanism, even when the words differ. This directly addresses the vocabulary-mismatch problem that keyword search cannot solve.

For patents, the strongest implementations apply semantic search at the claim level and across both patents and scientific literature. Claim-level retrieval matters because the legal risk in a patent lives in its claims, not its abstract. Searching patents and scientific papers together matters because early technical disclosure often appears in the literature before it reaches granted claims.

An R&D ontology strengthens semantic search further. An ontology is a structured map of technical concepts and their relationships. When semantic retrieval is organized through an ontology, the system interprets a query in the context of a technology domain rather than as isolated words, which improves both recall and precision.

What the shift changes for R&D and IP teams

Semantic search changes prior art and FTO work most directly. In prior art search, semantic retrieval surfaces conceptually relevant disclosures that keyword queries overlook, which strengthens both patentability assessments and invalidity arguments. In freedom-to-operate search, it surfaces active claims a product may read on even when those claims use unexpected language, reducing unquantified legal risk.

It also changes patent analytics. Once retrieval understands meaning, analytics can group filings by technical concept rather than by literal text, producing cleaner technology landscapes, competitor maps, and white space analysis. Agentic workflows build on this by chaining retrieval and reasoning steps to assemble landscapes, comparison matrices, and monitored positions automatically.

Where Cypris fits

Cypris is an AI-native R&D intelligence platform built on semantic search across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology lets Cypris interpret technical meaning and retrieve conceptually related patents and literature at the claim level, rather than matching keywords.

Cypris Q, the platform's agentic layer, chains semantic retrieval and reasoning into end-to-end workflows such as landscape analysis, prior art review, and FTO assessment. Agentic Monitoring keeps those positions current by evaluating new filings as they publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is semantic search for patents?

Semantic search for patents retrieves filings by meaning rather than by exact keywords, representing text as vectors so that conceptually similar patents sit close together. This surfaces relevant patents that use different terminology than a query expects, which keyword search cannot do.

What is the difference between semantic search and keyword search?

Semantic search matches the meaning of text, while keyword search matches exact terms combined with Boolean operators. Keyword search misses filings that describe the same invention in different words, whereas semantic search retrieves them because it operates on concepts rather than literal strings.

Why are R&D teams moving to AI-native patent search?

R&D teams are moving to AI-native patent search because the volume and linguistic variety of global filings have outpaced keyword methods, causing silent gaps in coverage. Semantic search retrieves conceptually related filings across patents and scientific literature, reducing the risk that critical disclosures are missed.

Is semantic search better than keyword search for prior art?

Semantic search is generally stronger for prior art because it surfaces conceptually relevant disclosures that keyword queries overlook due to vocabulary mismatch. Keyword search remains useful for targeted lookups when the exact terminology is known, so many workflows combine both.

What is an R&D ontology in patent search?

An R&D ontology is a structured map of technical concepts and their relationships that organizes a search corpus by meaning. In patent search, an ontology lets a system interpret a query in the context of a technology domain rather than as isolated words, improving both recall and precision.

Does semantic search work across patents and scientific papers?

Semantic search works across both patents and scientific papers when the corpus unifies them, which matters because early technical disclosure often appears in the literature before it reaches granted patent claims. Searching both together produces a more complete technical and competitive picture.

How does semantic search improve patent analytics?

Semantic search improves patent analytics by grouping filings by technical concept rather than literal text, which produces cleaner technology landscapes, competitor maps, and white space analysis. Analytics built on meaning are more reliable than analytics built on keyword matches alone.

Can semantic patent search be automated with agents?

Semantic patent search can be automated with agentic workflows that chain retrieval and reasoning steps to assemble landscapes, comparison matrices, and monitored positions. Agents keep the analysis current by re-running semantic retrieval against new filings as they publish.

Does semantic search replace Boolean patent search entirely?

Semantic search does not fully replace Boolean patent search, because targeted keyword queries remain useful when exact terminology is known. The strongest workflows combine semantic retrieval for recall with keyword precision for confirmation.

What data coverage does effective semantic patent search require?

Effective semantic patent search requires broad coverage across patents and scientific literature, so that conceptually related disclosures in any vocabulary can be retrieved. A corpus of more than 500 million patents and scientific papers organized through an R&D ontology supports this breadth.

‍

Semantic Search vs. Keyword Search for Patents: Why R&D Teams Are Moving to AI-Native Patent Search

Blogs

July 16, 2026

•

XX

min read

Patenting in artificial intelligence is growing faster than almost any other technology area, and generative AI is the sharpest example. According to the World Intellectual Property Organization, generative AI patent families grew from 733 in 2014 to more than 14,000 in 2023, an increase of over 800 percent, while related scientific publications rose even faster, from 116 to more than 34,000 over the same period.¹ WIPO's subsequent analysis shows the acceleration continuing: newly published generative AI patent families reached roughly 37,800 in 2025, and more were published in 2024 and 2025 combined than in the entire preceding decade.² This makes AI, and generative AI within it, one of the most active and fastest-moving areas of the global patent record.

Two structural features shape how the AI patent landscape must be read. The first is the gap between research and patents. Scientific publication in AI runs ahead of patenting and at higher volume, so the research literature is the leading edge of the landscape and patents are a lagging, commercial-commitment signal.¹ The second is publication lag: applications publish roughly eighteen months after filing, so the most recent windows of the landscape are systematically under-represented, and apparent slowdowns in the latest year are usually artifacts rather than real declines.² Any analysis that reads the latest patent counts without accounting for lag will misjudge the current state of a field moving this quickly.

The landscape is also highly concentrated, which matters for competitive positioning. Between 2014 and 2023, generative AI patenting was dominated by a small number of countries: inventors in China accounted for 38,210 patent families, followed by the United States with 6,276, South Korea with 4,155, Japan with 3,409, and India with 1,350, so the top four locations represented roughly 94 percent of all generative AI patenting.¹ The leading individual applicants over that period were Tencent with 2,074 families, Ping An with 1,564, and Baidu with 1,234, followed by the Chinese Academy of Sciences, IBM, Alibaba, Samsung, Alphabet, ByteDance, and Microsoft, and generative AI still represented only about 6 percent of all AI patent families, indicating substantial room for growth.¹ The broader picture is consistent: AI patents granted worldwide rose from 3,833 in 2010 to 122,511 in 2023, with China accounting for roughly 70 percent of grants, the United States about 14 percent, and Europe under 3 percent.⁵ WIPO's more recent analysis shows the concentration intensifying, with China publishing more than 43,000 generative AI families in 2024 and 2025 combined, exceeding its entire cumulative output from 2014 to 2023, and new entrants such as Nvidia rising into the top ranks.² WIPO further notes that most generative AI inventions are protected primarily in their domestic markets rather than through large international patent families, and it expects the fastest future growth in multimodal systems and AI agents, and in the integration of generative AI into sectors such as healthcare, finance, and energy.² This aligns with the broader enterprise shift to agentic AI: the Model Context Protocol has become the standard through which AI agents connect to external data,⁴ and Gartner projects that 40 percent of enterprise applications will include task-specific AI agents by the end of 2026.³ For organizations building or adopting AI, the practical implication is that the areas of heaviest future activity, including agentic AI, are identifiable now from the research and early-filing signal.

What the AI patent landscape shows

Rapid, accelerating growth. Generative AI patent families grew from 733 in 2014 to more than 14,000 in 2023 and to roughly 37,800 in 2025, with more published in 2024 and 2025 combined than in the preceding decade.¹,²

Research ahead of patents. Scientific publication in AI runs ahead of patenting and at higher volume, so the research literature is the leading edge and patents are a commercial-commitment signal.¹

Concentration. Activity is concentrated in a small number of organizations and geographies: China accounted for 38,210 generative AI families from 2014 to 2023, and the top four locations for roughly 94 percent of the total, led by applicants such as Tencent, Ping An, and Baidu.¹

By application. Among generative AI families from 2014 to 2023, image and video (about 18,000), text (about 13,500), and speech or music (about 13,500) dominate, while molecule, gene, and protein applications, though smaller at about 1,500, grew fastest at roughly 78 percent per year.¹

Granted patents worldwide. AI patents granted worldwide rose from 3,833 in 2010 to 122,511 in 2023, with China accounting for roughly 70 percent of grants, the United States about 14 percent, and Europe under 3 percent.⁵

Domestic protection. Most generative AI inventions are protected primarily in domestic markets rather than through large international families, which affects where freedom-to-operate risk sits.²

Emerging direction. The fastest future growth is expected in multimodal systems and AI agents, and in the integration of generative AI into healthcare, finance, and energy.²

How to analyze a fast-moving AI patent landscape

Scope the technology space with classification codes and concept-based search, since AI terminology evolves quickly and keyword-only boundaries miss relevant work.

Aggregate to the patent-family level, so a single invention filed across jurisdictions is counted once and international coverage is not conflated with volume.

Read scientific literature as the leading edge, because AI research precedes and exceeds patenting, so the earliest signal of a new direction is in publications.¹

Correct for publication lag, discounting the most recent windows, because applications publish about eighteen months after filing and the latest year is under-represented.²

Map concentration and white space, identifying which organizations and areas are crowded and which sub-areas, such as specific agentic or multimodal applications, remain open.

Monitor continuously, tracking the landscape over time so new filings and research are surfaced as they publish in a field that is changing rapidly.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving fields such as artificial intelligence across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters AI activity by concept across rapidly evolving terminology and normalizes organizations to canonical entities, so a team can resolve which areas and players are crowded and which sub-areas remain open as white space. Semantic search across patents and scientific literature reads the research leading edge, which is essential in AI because publication precedes and exceeds patenting, and connects it to early filings. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the scoping, clustering, attribution, and gap analysis. Agentic Monitoring tracks a defined AI area over time and flags new patents and papers as they publish, which is essential where recent activity is under-represented by publication lag. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is AI patenting growing? AI patenting is growing faster than almost any other technology area, and generative AI is the sharpest example. WIPO data show generative AI patent families grew from 733 in 2014 to more than 14,000 in 2023, an increase of over 800 percent, and to roughly 37,800 in 2025. More generative AI families were published in 2024 and 2025 combined than in the entire preceding decade.

What is the AI patent landscape? The AI patent landscape is the map of where artificial intelligence is being patented, which organizations are active, and where activity is concentrated or sparse. Because AI research runs ahead of patenting, the landscape is best read across both patents and scientific literature. It is one of the fastest-moving areas of the global patent record.

Why does AI patent analysis rely on scientific literature? AI patent analysis relies on scientific literature because research in AI precedes patenting and occurs at higher volume, so the literature is the leading edge of the field. Patents are a lagging, commercial-commitment signal. WIPO data show scientific publications in generative AI grew even faster than patents over the past decade.

Why does publication lag matter in the AI patent landscape? Publication lag matters because applications publish roughly eighteen months after filing, so the most recent windows of the AI patent landscape are systematically under-represented. In a field moving this quickly, apparent slowdowns in the latest year are usually artifacts of lag rather than real declines. Longer-window trends and continuous monitoring are more reliable.

Where is AI patenting concentrated? AI patenting is concentrated in a small number of organizations and geographies. WIPO's analysis shows organizations based in China prominent among the top generative AI filers, with generative AI still representing a modest share of the broader AI patent total. Most generative AI inventions are protected primarily in domestic markets rather than through large international families.

Where is AI innovation heading next? AI innovation is expected to grow fastest in multimodal systems and AI agents, and in the integration of generative AI into sectors such as healthcare, finance, and energy, according to WIPO. Because research precedes patenting, these directions are already visible in the publication and early-filing signal. Analyzing the landscape now identifies where future activity will concentrate.

Why aggregate AI patents into families? Aggregating AI patents into families avoids double-counting, because a single invention is often filed across multiple jurisdictions. Counting documents overstates activity and conflates international coverage with genuine volume. The patent family is the correct unit for measuring how much distinct AI invention is occurring.

How do you find white space in the AI patent landscape? Finding white space in the AI patent landscape means mapping patents and scientific literature across AI sub-areas, clustering activity by concept, and identifying the sparse sub-areas where few patents exist. Because AI terminology evolves quickly, semantic and concept-based analysis is essential. The sparse areas, such as specific agentic or multimodal applications, indicate where a defensible position remains available.

How do you keep an AI patent landscape current? Keeping an AI patent landscape current requires continuous monitoring, because AI moves quickly, new research and filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages within months. Cypris uses Agentic Monitoring to track a defined AI area and flag new patents and papers as they publish.

Who uses AI patent landscape analysis? AI patent landscape analysis is used by R&D, innovation, IP, and strategy teams at technology companies, and by organizations across sectors adopting AI, to understand where the technology is heading and where competitors are active. It is also used to identify white space for new AI inventions. Cypris serves hundreds of enterprise customers across research-intensive and regulated industries.

Endnotes

World Intellectual Property Organization (2024). Patent Landscape Report: Generative Artificial Intelligence. Geneva: WIPO. https://doi.org/10.34667/tind.49740
World Intellectual Property Organization (2026). Generative AI patent landscape update, WIPO Patent Analytics. https://www.wipo.int/en/web/patent-analytics/generative-ai
Gartner (2025). Gartner Predicts 40% of Enterprise Apps Will Feature Task-Specific AI Agents by 2026. https://www.gartner.com/en/newsroom/press-releases/2025-08-26-gartner-predicts-40-percent-of-enterprise-apps-will-feature-task-specific-ai-agents-by-2026-up-from-less-than-5-percent-in-2025
Anthropic (2025). Donating the Model Context Protocol and establishing the Agentic AI Foundation. https://www.anthropic.com/news/donating-the-model-context-protocol-and-establishing-of-the-agentic-ai-foundation
Stanford Institute for Human-Centered Artificial Intelligence (2025). Artificial Intelligence Index Report 2025, Chapter 1. arXiv:2504.07139. https://doi.org/10.48550/arxiv.2504.07139

‍

The AI Patent Landscape: Where Innovation in Artificial Intelligence Is Heading in 2026

Blogs

July 16, 2026

•

XX

min read

Patent search built for text doesn't work well for chemistry. A compound can be described with different names, different notation, or a Markush structure covering a whole class of molecules, all referring to the same underlying chemical entity. A keyword-based patent search treats these as unrelated results, even when the compounds are structurally identical or close enough to raise real FTO or novelty concerns. For R&D and IP teams in pharmaceuticals, chemicals, and advanced materials, this is a genuine gap: the patent search tool and the chemical structure search tool are usually separate products, and neither one alone gives a complete picture.

This matters at every stage of the R&D and IP workflow. A white space analysis that only checks patent text can miss a structurally overlapping compound published under an unfamiliar name. An FTO search that doesn't account for structural similarity can clear a compound that a structure-based comparison would have flagged. And prior art review that treats chemical literature and patents as separate searches duplicates effort while still leaving gaps between the two.

Why chemical structure search needs to be part of patent search

Naming doesn't map to structure. The same molecule can appear under IUPAC nomenclature, a trade name, a CAS registry number, or an informal lab designation across different patents and papers. Text-based patent search treats these as different entities unless someone manually reconciles them.

Markush claims cover more than they name. Patent claims in chemistry frequently use Markush structures to cover a genus of related compounds rather than naming each one individually. Assessing FTO or novelty against a Markush claim requires structural comparison, not keyword matching, since the specific compound in question may never appear by name in the claim text.

Scientific literature moves faster than patent filings in chemistry. A compound can appear in scientific research well before it's the subject of a patent application. Patent search that excludes scientific literature can miss the earliest indication that a structurally relevant compound is already being studied.

Structural similarity, not just exact matches, matters for FTO. Freedom-to-operate risk isn't limited to identical compounds — a structurally similar compound falling within a broad claim can carry the same infringement risk as an exact match, which text search has no way to detect.

How Cypris connects chemical structure search to patent analytics

Cypris runs patent search, patent analytics, FTO, and white space analysis on a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. That ontology is what lets a query connect a compound's structure to the concept it represents, rather than relying only on the vocabulary a specific patent or paper happens to use.

Because Cypris runs semantic search across patents and scientific literature together, a chemistry-focused query surfaces both patent claims and related scientific research on the same underlying compound or reaction class, rather than requiring two separate searches. The platform's agentic layer, Cypris Q, lets R&D and IP teams run multi-step queries — checking a compound against patent claims, related literature, and Markush coverage as a single agentic workflow rather than a manual, multi-tool process. Agentic Monitoring then keeps tracking a technology or compound area on an ongoing basis, surfacing new patents or papers that affect a cleared position as they publish.

Cypris also supports MCP (Model Context Protocol), so chemistry and IP teams can connect this corpus directly into their own AI agents and internal tools, rather than working through a standalone search interface. With enterprise API partnerships with OpenAI, Anthropic, and Google and enterprise-grade security, this supports AI implementation inside regulated R&D functions where compound data needs to stay protected.

Commercial research, ontological search, and agent systems in practice

Chemical structure search isn't only a legal or IP exercise — it's also a commercial research problem. Business development and licensing teams need to know who else is working on a structurally related compound before pursuing a partnership, and technology scouting for M&A due diligence depends on finding relevant chemistry regardless of how a target company has described it internally. Patent search and patent analytics that only serve the IP function miss this commercial research use case, even though it draws on the same underlying corpus of patents and scientific literature.

Ontological search is what makes both the IP and commercial research use cases work from a single system. Rather than matching text, ontological search organizes patents, scientific papers, and compound data around the technical concepts and structural relationships that connect them, so a query for a specific chemistry returns everything relevant to that concept — a competing patent claim, an academic paper describing the same reaction pathway, or a company's public disclosure of related research — regardless of the vocabulary each source uses. This is the same ontology-driven structure that supports FTO and white space analysis, applied to commercial and licensing questions instead of legal clearance.

Agent systems are what turn ontological search into an ongoing capability rather than a single query. Cypris Q operates as an agent system that can run a multi-step chemical structure and patent search — checking a compound against claims, literature, and commercial activity in one pass — while Agentic Monitoring keeps that same agent system watching a technology or compound area afterward, so a licensing team or IP function is notified when new patents, papers, or public research change the picture. Because these agent systems are accessible through MCP, both R&D and business development teams can query the same underlying chemical structure and patent data from within their own AI tools, rather than maintaining separate systems for IP work and commercial research.

Where Cypris fits

Cypris is built to close the gap between patent search, scientific literature search, and chemistry-specific analysis. Its corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology, connects claim language and scientific research to the underlying technical and chemical concepts they describe. Cypris Q and Agentic Monitoring turn a one-time chemistry-related patent search into an ongoing, agentic workflow, and MCP support lets that corpus plug directly into a team's own AI agents. With enterprise API partnerships with OpenAI, Anthropic, and Google and enterprise-grade security, Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries where patent search, patent analytics, FTO, and white space analysis depend on getting chemistry right.

FAQ

Is there a platform that searches patents and chemical structures together? Yes — platforms built for chemistry-focused R&D, such as Cypris, connect patent search to the underlying chemical concept rather than treating structure search and patent search as separate tools, using an ontology that maps compounds and claims to the same technical concept regardless of naming differences.

Why isn't keyword-based patent search enough for chemistry? Keyword-based patent search misses compounds described under different names, notations, or Markush structures, so it can overlook patents or papers that are structurally relevant even when the text doesn't match.

What is a Markush structure, and why does it matter for patent search? A Markush structure is a patent claim format that covers a broad genus of related chemical compounds rather than naming each one individually, which means assessing FTO or novelty against it requires structural comparison rather than keyword matching.

Does scientific literature matter for chemical patent search? Yes. Compounds and reactions often appear in scientific literature before they are the subject of a granted patent, so searching patents and scientific literature together surfaces relevant chemistry earlier than a patents-only search.

How does structural similarity affect freedom-to-operate (FTO) risk? FTO risk isn't limited to exact compound matches — a structurally similar compound that falls within a broad existing claim can carry meaningful infringement risk, which text-based patent search has no way to detect.

What role does AI play in chemical structure and patent search? AI enables semantic search and ontology-driven concept mapping, so a chemical structure query can be connected to relevant patent claims and scientific literature regardless of the specific naming convention used in each document.

What is agentic monitoring for chemistry-focused patent search? Agentic monitoring is the ongoing, automated tracking of a compound or technology area after the initial search, surfacing new patents or scientific papers relevant to that chemistry as they are published.

How does MCP (Model Context Protocol) apply to chemistry and patent research? MCP lets R&D and IP teams connect a patent, scientific literature, and chemical structure corpus directly into their own AI agents, rather than working through a separate, standalone search tool.

Which industries need combined patent and chemical structure search? Pharmaceuticals, chemicals, and advanced materials R&D teams rely most heavily on combined patent and chemical structure search, since compound novelty and FTO risk in these industries depend on structural comparison, not just text matching.

Is Cypris only useful for chemistry-focused teams? No — Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries, supporting patent search, patent analytics, FTO, and white space analysis broadly, with chemical structure context available where relevant.

Is chemical structure search only useful for IP and legal teams? No. Commercial research use cases like licensing scouting, partnership evaluation, and M&A due diligence rely on the same chemical structure and patent search capability as FTO and prior art work, since both depend on finding structurally relevant compounds regardless of how they are named or described.

What is ontological search in the context of chemical structure and patent search? Ontological search organizes patents, scientific papers, and compound data around the technical concepts and structural relationships connecting them, so a query returns everything relevant to a chemistry regardless of the specific vocabulary or naming convention each source uses.

What are agent systems, and how do they apply to chemical patent search? Agent systems are AI-driven layers, like Cypris Q, that run multi-step chemical structure and patent search as a single ongoing process rather than a one-time query, and that continue monitoring a compound or technology area afterward through agentic monitoring.

‍

Chemical Structure Search for Patents and Scientific Literature: What R&D and IP Teams Need in 2026

Blogs